Last edition
News about
Study Design solution evaluates a protocol's feasibility by comparing it to similar trials using Braid, Advarra's newly launched data and AI engine. Braid is powered by a uniquely rich set of digitised protocol-related documents and operational data from over 30,000 historical studies conducted by 3,500 sponsors.
GSK to Invest USD 30 Billion in US R&D and Supply Chain Over Next 5 Years
GSK has announced plans to invest USD 30 billion across the United States over the next five years to strengthen its R&D, drug discovery, development, and clinical trial activity.
ExSight Ventures Invests in RevOpsis Therapeutics to Develop Eye Disease Therapies
RevOpsis is developing a novel class of multi-specific antibody-based treatments designed to address significant unmet needs in ophthalmology, with an initial focus on wet Age-related Macular Degeneration (AMD) and diabetic eye disease.
Sanguine Expands Oncology Biospecimen Access via Clinic Partnerships
Through these partnerships, Sanguine now offers researchers access to a growing inventory of oncology biospecimens, including blood, plasma, serum and peripheral blood mononuclear cells (PBMCs), collected using minimally invasive methods to reduce donor burden and accelerate study timelines.
Lilly to Establish USD 5 Billion API Manufacturing Facility in Virginia
The new site in Virginia marks the first of four new US manufacturing sites that Lilly plans to announce this year.
IceCure Gets Regulatory Approval in Israel for XSense Cryoablation System
XSense is now approved in Israel for all indications for which ProSense has already received approval in Israel, including general surgery, dermatology neurology, including cryoanalgesia, thoracic surgery, ENT (Ear, Nose, Throat), gynaecology, oncology (including benign and malignant breast tumors), proctology and urology.
Ocugen and Kwangdong Finalise OCU400 Gene Therapy Deal for Retinitis Pigmentosa in Korea
Pursuant to the licence agreement, Ocugen will receive upfront license fees and near-term development milestones equaling up to USD 7.5 million. The company will be entitled to sales milestones of USD 1.5 million for every USD 15 million of sales in Korea, projected to reach USD 180 million or more in the first 10 years of commercialisation.
Novo Nordisk presented new findings from its Wegovy and Cagrilintide trials in obesity management at the ongoing European Association for the Study of Diabetes (EASD) 2025 congress in Vienna, Austria.
AVITA Medical Receives CE Mark for RECELL GO
With the CE Mark secured, AVITA Medical will begin commercialisation of RECELL GO in select European countries, including Germany, Italy and the United Kingdom, in collaboration with burn centres and clinical partners.
Gyala Therapeutics Unveils CD84 CAR-T with Strong Pre-clinical Results in Tough Leukemias
Gyala secures €3 million financing from Invivo Partners, Nara Capital and CDTI Innvierte to launch a Phase I trial in AML patients in H2 2025
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy